Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DASATINIB Cause Peripheral arterial occlusive disease? 41 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 41 reports of Peripheral arterial occlusive disease have been filed in association with DASATINIB (dasatinib). This represents 0.1% of all adverse event reports for DASATINIB.

41
Reports of Peripheral arterial occlusive disease with DASATINIB
0.1%
of all DASATINIB reports
3
Deaths
14
Hospitalizations

How Dangerous Is Peripheral arterial occlusive disease From DASATINIB?

Of the 41 reports, 3 (7.3%) resulted in death, 14 (34.1%) required hospitalization, and 1 (2.4%) were considered life-threatening.

Is Peripheral arterial occlusive disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DASATINIB. However, 41 reports have been filed with the FAERS database.

What Other Side Effects Does DASATINIB Cause?

Pleural effusion (2,424) Fatigue (2,173) Death (1,741) Nausea (1,740) Diarrhoea (1,728) Headache (1,625) Adverse event (1,382) Rash (1,300) Drug ineffective (1,271) Hospitalisation (1,181)

What Other Drugs Cause Peripheral arterial occlusive disease?

NILOTINIB (319) METHOTREXATE (120) ADALIMUMAB (116) RIVAROXABAN (101) PONATINIB (90) IMATINIB (86) ASPIRIN (77) ATORVASTATIN (70) METOPROLOL (70) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (63)

Which DASATINIB Alternatives Have Lower Peripheral arterial occlusive disease Risk?

DASATINIB vs DATOPOTAMAB DERUXTECAN-DLNK DASATINIB vs DAUNORUBICIN DASATINIB vs DAXIBOTULINUMTOXIN A-LANM DASATINIB vs DAYTRANA DASATINIB vs DECITABINE

Related Pages

DASATINIB Full Profile All Peripheral arterial occlusive disease Reports All Drugs Causing Peripheral arterial occlusive disease DASATINIB Demographics